Medpagetoday -- Patients with inflammatory arthritis who have anti-cyclic citrullinated peptide (anti-CCP) antibodies have more severe disease and show less benefit from treatment than those who are antibody negative, British researchers found.
Medpagetoday -- Patients with inflammatory arthritis who have anti-cyclic citrullinated peptide (anti-CCP) antibodies have more severe disease and show less benefit from treatment than those who are antibody negative, British researchers found.
